MO · Q1 2026 Earnings

The H1/H2 cadence flipped from "weighted to second half" to "more balanced" — a downgrade dressed as an update. Last quarter management explicitly told investors FY2026 EPS growth would be H2-weighted because of upfront import-export costs in H1. Three months later, after a $1.32 Q1 print (+7.3% YoY) that clearly exceeded the implied trajectory, the framing shifts to: "We now expect 2026 adjusted diluted EPS growth to be more balanced between the first half and the second half of the year." That sentence is doing more work than it looks. It means H1 has overshot AND H2 expectations have been lowered enough to keep the FY range unchanged — yet the range itself wasn't raised. Asked directly on the call why guidance wasn't raised or narrowed, Mancuso said "we thought it was prudent to reaffirm guidance... we're a quarter into the year. Obviously, the macroeconomic environment remains challenging and uncertain." A management team confident in the upside would have nudged the low end up. They didn't.

The eVapor narrative finally turned defensive. Several quarters ago illicit-vape enforcement was the cross-category tailwind helping cigarette volumes. This quarter it's a guidance caveat: "after several years of rapid growth, we began to see signs of moderation in the back half of 2025...we believe these developments suggest early indications that the category's prior growth trajectory...may be evolving." eVapor moderation is now a constraint on combustible AND e-vapor volumes — the cross-category tailwind narrative has run its course, and management is conceding it before the data forces them to.

Macro language entered the reaffirmed-guidance caveats. "Increased macroeconomic uncertainty facing adult nicotine consumers" is bolted onto the FY guide reaffirmation — a caveat not in the prior reaffirmed caveat list per trusted prior guidance. Gifford emphasized on the call that "the consumer does remain under pressure" and gas prices increased significantly later in the quarter. If FY2026 lands at the low end, management has pre-positioned macro as the explanation. That's the textbook structure of a guide that's quietly de-risked rather than confidently reiterated.

The eVapor re-entry posture remains conservative. In prepared remarks Gifford reiterated that progress is "constrained by the limited number of FDA authorized products" and that the company sees the path forward as both enforcement AND a faster FDA authorization framework — implying capital deployment into eVapor is gated on regulatory progress, not just illicit-share trends. (See Q&A section for additional color on the disciplined re-entry stance.)

Three FY line items disappeared without explanation. Tax rate (22.5–23.5%), CapEx ($300–375M), and D&A (~$225M) were all in the prior FY2026 guidance framework as reaffirmed line items, and all three are absent from this quarter's framework — not "withdrawn" with a reason, just gone. CapEx in particular is the central FY2026 P&L story for the import/export build-out. The silence on whether that step-up is still on track is conspicuous.